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Abstract 
Status epilepticus (SE) is the maximal expression of epilepsy with a high morbidity 
and mortality. It occurs due to the failure of mechanisms that terminate seizures. 
Both human and animal data indicate that the longer a seizure lasts, the less likely it 
is to stop. Recent evidence suggests that there is a critical transition from an ictal to 
a post-ictal state, associated with a transition from a spatio-temporally 
desynchronized state to a highly synchronized state, respectively. 
As SE continues, it becomes progressively resistant to drugs, in particular 
benzodiazepines due partly to NMDA receptor-dependent internalization of GABA(A) 
receptors. Moreover, excessive calcium entry into neurons through excessive NMDA 
receptor activation results in activation of nitric oxide synthase, calpains, and NADPH 
oxidase. The latter enzyme plays a critical part in the generation of seizure-
dependent reactive oxygen species. Calcium also accumulates in mitochondria 
resulting in mitochondrial failure (decreased ATP production), and opening of the 
mitochondrial permeability transition pore. Together these changes result in status 
epilepticus-dependent neuronal death via several pathways. Multiple downstream 
mechanisms including inflammation, break down of the blood-brain barrier, and 
changes in gene expression can contribute to later pathological processes including 
chronic epilepsy and cognitive decline.  
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1 Introduction 
Although most seizures last a brief time (secondarily generalized seizures last less 
than 2 minutes[1]), occasionally seizures can become more prolonged, and are then 
considered as a separate entity – status epilepticus (SE) - because of the associated 
high morbidity and mortality[2,3]. It has long been recognized that the hippocampus 
is particularly vulnerable to damage by prolonged seizures[4]. In 1880, Pfleger 
described hemorrhagic lesions in the mesial temporal lobe of a patient dying in status 
epilepticus, and he concluded that neuronal necrosis was the result of impaired blood 
flow or metabolic disturbances that occurred during the seizures[5]. More recently, 
postmortem studies have revealed significant acute neuronal loss in the hippocampi 
of patients dying in convulsive status epilepticus and MRI studies have also shown 
progressive atrophy of the hippocampus in people following status epilepticus[6,7]. 
With prolonged refractory status epilepticus, general brain atrophy has been found, 
although it is not clear whether this was the result of the SE or the treatment, in 
particular prolonged general anesthesia [8]. A recent postmortem study of unselected 
patients demonstrated that there are patients who have had episodes of status 
epilepticus with no evidence of damage in the hippocampus, suggesting that status 
epilepticus alone may not be sufficient to cause neuronal damage[9]. 
The long-standing definition of status epilepticus was a seizure that lasted longer 
than 30 minutes, but this definition lacks clinical utility[10]. In addition, a greater 
understanding of the pathophysiology of status epilepticus has led to a redefinition of 
status epilepticus[11]. This definition recognizes that status epilepticus can be 
defined by two distinct pathophysiological processes – those that lead to 
prolongation of the seizure and those that lead to its pathophysiological 
consequences. As I will discuss below, these processes are not necessarily mutually 
exclusive. The new definition [11] is: “SE is a condition resulting either from the 
failure of the mechanisms responsible for seizure termination or from the initiation of 
mechanisms which lead to abnormally prolonged seizures (after time point t1). It is a 
condition that can have long-term consequences (after time point t2), including 
neuronal death, neuronal injury, and alteration of neuronal networks, depending on 
the type and duration of seizures.” 
Status epilepticus is not uncommon affecting 10-41 per 100,000 per year[12]. 
Approximately 4-16% of people with epilepsy will have at least one episode of status 
epilepticus[13], and approximately half the episodes of status epilepticus occur in 
people with no prior history of epilepsy[14]. Status epilepticus has a mortality of 10-
20%, although recent data indicates that more rapid treatment regimens that have 
been instigated in the 21st century have resulted in a fall in mortality[15,16]. In 
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addition, those that survive status epilepticus have associated cognitive and 
neurological deficits, and importantly status epilepticus is a risk factor in those 
without epilepsy for the development of chronic epilepsy[17]. Acute symptomatic 
status epilepticus has a three-fold risk of resulting in chronic epilepsy compared to 
acute symptomatic seizures[17]. Status epilepticus, importantly, can be caused by a 
range of etiologies (Fig. 1) [14], and etiology is often the main determinant of 
prognosis[18]. Here, I will consider three clinically relevant aspects to the 
pathophysiology of status epilepticus: why seizures persist, how prolonged seizures 
become drug resistant and lastly the mechanisms underlying neuronal death and 
those that may eventually drive cognitive decline and the increased risk of epilepsy. 
 
2 Why do seizures persist? 
2.1 Termination of seizures 
A host of different biological processes have been proposed to lead to seizure 
termination including neurotransmitter depletion, ATP depletion, ionic changes, 
acidosis, increased GABAergic drive, release of adenosine, and release of 
peptides[19]; suppression or failure of these processes may promote status 
epilepticus. Moreover, there may be pro-seizure processes occurring during the 
development of status epilepticus including breakdown of the blood-brain barrier, 
inflammation, and increased expression of pro-epileptogenic peptides[20,21]. 
Furthermore, it has been observed that spatial and temporal synchronization occur 
before seizure and status epilepticus termination[22]. Indeed, effective treatment of 
status epilepticus seems to promote spatial synchronization prior to status epilepticus 
termination. This has led to a further examination of seizure dynamics prior to seizure 
termination, which found increased spatial and temporal synchronization, slowing of 
the frequency of mean power and flickering (fluctuations between ictal and post-ictal 
EEG variance values, measured over small, 50 ms, intervals)[23]. These 
observations have led to the concept that there is a critical transition from an ictal to 
a post-ictal state (Fig. 2).  
 
2.2 Nature of status epilepticus 
Status epilepticus can then be viewed as a failure to cross that transition. Status 
epilepticus can be considered as repetitive approaching and then retreating from the 
critical transition. This results in a decrease in the frequency of mean power and an 
increase in autocorrelation followed by the converse[23]. Such variation may explain 
the cyclical nature of the EEG and clinical manifestations of status epilepticus that 
have been described[24]. From a biological perspective, this can be viewed as a 
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failure of processes that “push” the seizure towards the post-ictal state. “Reinforcing” 
these processes with medication, eg by increasing GABAergic inhibition can 
therefore drive the brain state towards the post-ictal state.  
The animal models of de novo status epilepticus give us some insight into the 
progression towards status epilepticus. What is required in these models is 
something that drives persistent seizure activity. Stimulation protocols in which 
seizure activity is “driven” for more than 30 minutes becomes self-perpetuating ie 
once the stimulation is stopped self-sustaining status epilepticus continues; indeed, 
the longer the stimulation, the greater the chance of self-sustained status epilepticus 
(Fig. 3) [25,26]. This points to an exhaustion of those processes necessary for 
seizure termination and/or a strengthening of those processes that drive seizure 
activity. In most animal models, status-epilepticus can then be suppressed or 
terminated with drugs; anesthetic doses may be necessary. Status epilepticus can, 
however, then recur, which may contribute to the pathophysiological outcome, but 
nevertheless the status epilepticus eventually resolves [27].  
 
2.3 Nature of refractory status epilepticus 
Human observation tells an even more complex story. It has certainly been observed 
that the longer a seizure continues, the less likely it is to stop[28–30]; this is 
consistent with the concept that seizure activity itself can exhaust seizure inhibitory 
mechanisms (or strengthen seizure-promoting processes). Most people with status 
epilepticus have their status epilepticus stopped with initial therapy or even with 
second- or third-line therapies. This is consistent with the two-state model and a 
failure of crossing the transition (Fig. 2). However, there are a proportion that go on 
to super-refractory status epilepticus, “status epilepticus that continues or recurs 24 
hours or more after the onset of anesthetic therapy, including those cases where 
status epilepticus recurs on the reduction or withdrawal of anesthesia”[31]. The 
existence of super-refractory status epilepticus indicates that in some cases the post-
ictal state does not exist as a stable state and so once the anesthesia is removed the 
brain reverts to the ictal state. In my opinion, there are two main reasons why this 
may be so and these different reasons point to distinct therapeutic approaches (Fig. 
2). First, there may be an ongoing pathological process (eg infection or autoimmune 
disease) that drives the brain back into seizure activity. This can be addressed by 
treating the underlying pathological process, or stopping seizure activity with 
anesthesia until the underlying etiology has resolved. Second, the underlying 
pathology and/or the status epilepticus has resulted in changes to the brain that 
make the post-ictal state intrinsically unstable. This latter process could be the result 
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of permanent or semi-permanent changes such as neuronal death (in particular the 
death of interneurons), inflammation, break down of the blood-brain barrier, altered 
network connectivity, altered receptor/ion channel expression and altered 
neurotransmitter release. The treatment approach here is more complex, and there is 
no clear guidance from clinical or pre-clinical studies. The addition of multiple 
medications may make the post-ictal state more stable. There may be other ways of 
altering the stability of the post-ictal state including surgery, and brain stimulation. 
Following SE, EEG patterns that suggest an unstable state such as periodic 
lateralized epileptiform discharges, burst suppression patterns, or “after SE ictal 
discharges” (ASIDs) defined as ictal EEG activity lasting at least 10 seconds to a few 
minutes that starts and stops abruptly, and which is not associated with a clinical 
change, are associated with a high mortality (40-60% within 30 days of the cessation 
of status epilepticus)[32]. 
 
3 Drug resistance and acute receptor changes 
An observation in animal models is that the longer status epilepticus continues the 
harder it is to treat[33–35]. One explanation can immediately be appreciated from the 
section above. If there are biological processes that “push” the brain from an ictal to 
a post-ictal state, then as these become exhausted or as the processes that drive the 
brain into an ictal state become strengthened so any treatment will necessarily have 
to have a larger effect. This is the concept of “worse disease needs stronger 
treatments.” 
 
3.1 Changes in GABA(A) receptors 
There are, however, other more specific biological processes at play.  It has long 
been recognized that benzodiazepines lose their potency as status epilepticus 
continues and that this is partly due to the internalization of synaptic (gamma-
subunit) containing GABA(A) receptors[35–37]. This involves the activation of NMDA 
receptors and then calcineurin-dependent internalization of the GABA(A) 
receptors[38,39]. This process points to three specific treatment approaches. First, 
inhibition of NMDA receptor may increase the potency of benzodiazepines; this has 
been observed in animal models of status epilepticus[40–42]. Second, calcineurin 
antagonists would be predicted to have the same effect. Lastly, therapeutic 
strategies that target the extrasynaptic (gamma-subunit lacking) GABA(A) receptors 
should be more effective late-on in status epilepticus. Anesthetics and in particular, 
neurosteroids, target these extrasynaptic GABA(A) receptors and have been shown 
to be effective in benzodiazepine-resistant status epilepticus[43–45]. Lastly, the 
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resistance to GABAergic drugs may not be solely the result of changes in receptors 
but also in the phosphorylation state of the potassium-chloride transporter, KCC2, 
resulting in KCC2 internalization, elevated levels of intracellular chloride and 
consequent decreased inhibitory efficacy of GABA(A) receptor activation[46]. 
 
3.2 Other changes 
This process of acute receptor changes is not restricted to GABA(A) receptors. 
NMDA receptor expression increases in excitatory cells, presynaptic adenosine A1 
receptor and GABA(B) receptor expression is decreased, and AMPA receptors lose 
their GluA2 subunit[25,47–49]. GluA2-lacking AMPA receptors are calcium 
permeable and may contribute to calcium accumulation, possibly leading to neuronal 
death[48]. These findings indicate a role for glutamate receptor antagonists in status 
epilepticus, and, in particular, NMDA receptor antagonists as a means of modifying 
the condition (possibly preventing drug resistance). 
It is not only changes in receptors that could have an impact on drug sensitivity but 
also the increased aberrant expression of drug transporter proteins in response to 
status epilepticus that may promote resistance to certain antiepileptic drugs[50]. A 
recent study, however, found no impact of genetic knockout of p-glycoprotein on the 
response of status epilepticus induced by intrahippocampal kainic acid to 
antiepileptic drugs and there was no upregulation of P-gycoprotein in this model[51]. 
This study indicates that P-glycoprotein is not involved in the mechanisms explaining 
drug resistance in this model of focal status epilepticus, but does not exclude a role 
for other drug transporters or a role in other models of SE[51].  
 
 
4 Neuronal death and dysfunction 
 
4.1 Neuronal death and calcium 
A myriad of changes occurs in the days and weeks following status epilepticus. Many 
of these are driven by changes in gene expression due to changes in transcription 
factors, microRNA expression and DNA methylation. I will, here, confine myself to 
some of the more acute changes that occur in status epilepticus that have a direct 
bearing on the acute pathophysiology.  
The most obvious impact of status epilepticus is neuronal death. Specific groups of 
neurons seem to be more susceptible and neuronal death is usually more obvious in 
the hippocampus, in particular in the hilus, CA3 and CA1 regions – the precise 
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spatial and temporal pattern in animal models seems to be model, strain and age 
dependent[52–54]. 
Prolonged convulsive seizures can lead to physiological compromise including 
hypotension, hypoxia and acidosis that contribute to neuronal damage. However, 
seminal experiments by Meldrum and colleagues in baboons in the 1970’s 
demonstrated that seizure activity, itself, can cause neuronal damage[55,56]. This 
neuronal damage is dependent upon calcium entry and accumulation in neurons[57]. 
NMDA receptors are key in this process. Inhibition of NMDA receptors or calcium 
entry through NMDA receptors is neuroprotective in vitro[58–60] and in vivo[61,62]. 
Ca2+ permeable AMPA receptors may also play a role[48]. During the development of 
status epilepticus and as a result of neuronal death, ATP is released into the 
extracellular fluid and can activate P2X receptors, which may also permit calcium 
entry into neurons and glia and may play a role in neuro-inflammation and neuronal 
death[63]. 
 
4.2 Enzymes activated by intracellular calcium accumulation 
The downstream mechanisms from calcium entry and accumulation are less clear. 
Calcium entry can activate several enzymes that have been implicated in neuronal 
death. Although apoptosis through activation of caspase 3 has been proposed to be 
a major pathway leading to neuronal death following status epilepticus[64], more 
recent evidence suggests that this pathway plays no or only a minor role[65,66]. 
Other enzymes that have been implicated include the calpains - calcium-dependent, 
non-lysosomal cysteine proteases [67]. Members of the calpain family, however, 
have different targets and their activation results in a complex array of protein 
degradation with calpain 1 activation having predominantly neuroprotective effects 
whilst calpain 2 activation is neurotoxic[68,69]. These calpains may be activated to 
different degrees in different neuronal subtypes, perhaps explaining patterns of 
neuronal death in status epilepticus[69]. Nitric oxide synthase (NOS) is also activated 
by calcium entry through NMDA receptors. NOS exists as three different isoforms: 
neuronal NOS and endothelial NOS, which are both activated through cellular 
calcium entry, and inducible NOS, which is constantly active and not regulated by 
intracellular calcium concentrations[70]. Inducible NOS is mainly present in 
inflammatory cells, and inhibition of this may reduce inflammation and neuroprotect 
following status epilepticus [71]. Nitric oxide, which usually plays an important 
physiological role, when overproduced can combine with reactive oxygen species 
(see below) to produce peroyxnitrite, which at high concentrations is neurotoxic 
resulting in DNA injury, lipid peroxidation, impairment of cellular signaling, and 
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mitochondrial dysfunction [72,73]. However, in status epilepticus, nitric oxide may 
play a more important role in neuronal damage through increasing calcium release 
from internal stores through activation of ryanodine receptors[74].  
 
4.3 Mitochondrial dysfunction 
Perhaps one of the main routes from calcium entry to neuronal dysfunction and 
death is through mitochondrial dysfunction. Mitochondria are one of the main buffers 
of cytosolic calcium, taking up calcium predominantly through the mitochondrial 
calcium uniporter[75]. Calcium uptake by mitochondria activates mitochondrial 
respiratory chain function and can increase mitochondrial ATP (and free radical) 
production through activation of calcium-dependent NADH dehydrogenases[75]. 
However, excessive mitochondrial calcium accumulation has two main detrimental 
effects. First, calcium accumulation can result in mitochondrial membrane 
depolarization[60]. Since the mitochondrial membrane potential is necessary for ATP 
production, this can result in decreased ATP production and consequently cellular 
energy failure[60]. Energy failure results in a decrease in the cell’s ability to maintain 
ionic gradients, and so results in cellular depolarization, hyperexcitability and 
eventually cell death. Increasing ATP production during seizure activity by providing 
substrate, such as pyruvate, for mitochondria can prevent neuronal death[60,76]. 
Second, excessive calcium and reactive oxygen species production can result in 
opening of the mitochondrial permeability transition pore (mPTP). The mPTP is 
permeable to pro-apoptotic proteins such as cytochrome c[77]. mPTP opening also 
leads to further depolarization of the mitochondrial membrane potential with a 
consequent decrease in ATP production, disordered ionic homeostasis and 
mitochondrial matrix swelling.  
 
4.4 Reactive oxygen species 
Another major consequence of intracellular calcium accumulation and excessive 
activation of NMDA receptors is the overproduction of reactive oxygen species. 
Mitochondrial calcium accumulation can result in increased mitochondrial reactive 
oxygen species (ROS) production[78]. ROS can further contribute to mPTP opening 
through release of internal calcium stores via activation of ryanodine receptors and 
inhibition of sarcoplasmic reticulum calcium-ATPase[78]. Although ROS production 
during prolonged seizure activity was attributed to mitochondria[79], more recent 
evidence suggests that seizure-activity results in mitochondrial failure with reduced 
mitochondrial ROS production[80]. Seizure-induced ROS is probably generated 
through NMDA receptor-dependent, calcium-independent activation of NADPH 
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oxidase[80,81]. Then, later ATP depletion results in adenine formation and an 
increase in hypoxanthine and xanthine, substrates for xanthine oxidase, which also 
generates ROS[80]. NADPH oxidase activity is increased during seizure-activity[81]. 
Inhibition of NADPH oxidase can neuroprotect in in vivo models of status 
epilepticus[82–84]. As previously described ROS and consequent peroxynitrite 
formation can contribute to cell death though lipid peroxidation, inactivation of 
enzymes, mPTP opening and DNA damage. Moreover, ROS can directly inhibit 
mitochondrial complex 1 activity, further impeding ATP production[85,86]. ROS 
induced DNA damage can lead to activation of poly (ADP-ribose) polymerase 
(PARP), a repair enzyme. Excessive PARP activation can further lead to rapid ATP 
depletion which can also stimulate cascades leading to cell death[87]. 
Overall, it is likely that mitochondrial failure and excessive ROS production are the 
main pathways leading to the acute SE-induced pathology (Fig. 4). Importantly 
targeting these acute mechanisms may prevent downstream consequences, but it is 
likely that these need to be targeted early in the condition. With time, calcium 
accumulation, neuronal death, ROS production, and ATP depletion will activate other 
pathways, and additional downstream mechanisms likely contribute to the longer-
term consequences of status epilepticus, including chronic epilepsy and cognitive 
problems. 
 
5 Conclusion and future perspectives 
Our understanding of status epilepticus is burgeoning on several fronts. We are 
beginning to understand better the mechanisms that lead to the failure of termination 
of seizure activity, and those that lead to resistance to drug therapy. Continued 
progress is also being made in determining the mechanisms leading to status 
epilepticus-induced neuronal death. However, the relative importance of a variety of 
downstream mechanisms that result in the later consequences of status epilepticus 
including chronic epilepsy and cognitive decline is still unclear, and it is possible that 
under differing circumstances, the role of individual processes may vary. This 
suggests that either biomarkers will be necessary to direct the most appropriate 
therapy or polytherapy targeting a range of mechanisms will be necessary to prevent 
the many consequences of status epilepticus. 
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Figure legends 
 
Figure 1: Causes of status epilepticus in children and adults. CVA = cerebrovascular 
accident, CNS inf = CNS infection, Low AEDs = low antiepileptic drug levels in 
someone with epilepsy, Drug OD = drug overdose, EtOH = alcohol related, Remote = 
remote symptomatic. After ref [14] 
 
Figure 2: Seizure termination is due to a critical transition. (A) There is an ictal state 
with high variance over short time windows (50ms) and a post-ictal state with low 
variance. The transition from ictal to post-ictal involves flickering (periods of high 
alternating with low variance). (B) The proportion of different variance in ictal, post-
ictal and flickering periods. (C) Mid-seizure, there is predominantly high variance 
during the seizure period. During transition the variance distribution is split between 
pre-ictal, ictal and post-ictal states. (D) Graphic illustration of the stable ictal period, 
inhibitory mechanisms move the ball to the transition state and then into the stable 
post-ictal state. (E) Status epilepticus occurs when there is insufficient inhibition or 
drivers pushing the ball into the ictal state, so that the transition point may be 
approached but not crossed. (F) Refractory status epilepticus is either because there 
is a persistent driver into the ictal state (eg persistent etiology) or the landscape 
(neuronal network) has changed so that a stable post-ictal state no longer exists. 
Panels A-C are reproduced from ref [23] with permission 
 
Figure 3: The longer in vivo perforant path stimulation continues the greater the 
number of animals going into self-sustained status epilepticus (SE). After ref [25] 
 
Figure 4: Putative mechanisms leading to neuronal death following calcium (and 
sodium) entry through NMDA receptors. NMDA receptor activation and calcium entry 
activate several enzymes including calpains, NADPH oxidase (NOX) and N nitric 
oxide synthase (NOS). Reactive oxygen species and nitric oxide form peroxynitrite, 
which is toxic to DNA, proteins and lipids. Calcium from the cytosol is taken up by 
mitochondria and excessive mitochondria load results in decreased ATP production, 
energy failure and failure to maintain cellular ionic gradients. Mitochondrial calcium 
accumulation and reactive oxygen species contribute to the formation of the 
mitochondrial permeability transition pore (mPTP), which further disrupts 
mitochondrial function, but also permit cytochrome c into the cytosol where it can 
activate apoptotic pathways.  
